MedPath

Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy

Phase 4
Conditions
Safety
Drug Effect
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics
Recovery
Interventions
Registration Number
NCT05406102
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Brief Summary

Gastroenteroscopy diagnosis and treatment drugs need to meet the needs of quick onset, quick recovery and less anesthesia complications. Remimazolam is an anesthetic sedative independently developed by China. It is a new short-acting GABA(A) receptor agonist. Remimazolam has the advantages of rapid onset, rapid recovery, antagonist, controllable degree of cardiovascular and respiratory depression, low incidence of hypotension and respiratory depression. However, elderly patients as important and special patients, there are still a lack of relevant studies and reports.

In order to verify the safety and effectiveness of remimazolam in the gastroenteroscopy treatment of elderly patients, it can reduce the incidence of intraoperative hypotension or respiratory depression rate, improve the quality of recovery of elderly patients.

Detailed Description

Patients are fasted for at least 6 hours and water for at least 2 hours. After entering the gastroscopic room, patients took 0.1 g of dacronin hydrochloride glue in the throat for about 5 minutes, instructed the patient to be in the left recumbent position and nasal catheter oxygen (4 L / min), finger oxygen and blood pressure ; after static pushing sufentanil 0.08 μg/kg, respectively, give remimazolam or propofol for sedation; MOAA/S score ≤ 3 , start gastrointestinal endoscopy, maintain MOAA/S ≤ 4 during the operation. After the end of gastrointestinal treatment, the patient is moved to the recovery room for recovery. The evaluators also assessed the incidence of blood oxygen saturation \< 90%, the incidence of respiratory rate \< 8 times/min, the incidence of hypotension, the time of improved aldrete≥9, the time of discharge score ≥9 points, the postoperative cognitive function, amnesia, anxiety, dizziness, pain, nausea, and adverse events.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Age ≥60, no gender limitation;
  • Patients receiving gastroscopy or gastrointestinal endoscope;
  • ASA physical status score of I to III;
  • 18 kg/m² < BMI < 30kg/m²;
  • They clearly understand and voluntarily participate in the study and sign informed consent
Exclusion Criteria
  • Endoscopic diagnosis and treatment techniques with complex operation are required;
  • Patients with respiratory management difficulties;
  • Anemia or Thrombocytopenia;
  • Have a history of drug abuse and/or alcohol abuse within 2 years prior to the beginning of the screening period;
  • Patients with hypertension whose blood pressure is not satisfactorily controlled by antihypertensive medication (sital systolic blood pressure ≥160 mmHg at screening stage, and/or diastolic blood pressure ≥100 mmHg at screening stage);
  • Allergic or contraindicated to benzodiazepines, opioids, propofol, lidocaine and their components;
  • Participated in clinical trials of other drugs as a subject within the last 3 months;
  • The investigator considered the patients unfit to participate in the trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Remimazolam groupRemimazolamPatients were slowly injected of 0.08 ug/kg of sufentanil. Patients received remimazolam 0.1mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
Propofol groupPropofol groupPatients were slowly injected of 0.08 ug/kg of sufentanil for 1 min during the examination.Patients received Propofol 1.5mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
Primary Outcome Measures
NameTimeMethod
Incidence of hyoxemiatwo hours

The proportion of blood oxygen saturation \< 90%.

Secondary Outcome Measures
NameTimeMethod
Incidence of hypotensiontwo hours

The incidence of systolic blood pressure decreased by more than 20% before sedation or systolic blood pressure decreased to ≤ 80 mmHg.

Postoperative cognitive decline ratetwo hours

Changes in MOCA score before and after surgery

Incidence of respiratory depressiontwo hours

The incidence of respiratory rate \< 8 times/min

The time of Improved Aldrete≥9two hours

improved Aldrete≥9 was evaluated every 1 min after the last administration, and the time from the last administration to improved Aldrete score ≥9 .

The time of discharge score ≥9two hours

the discharge score was evaluated every 3 minutes after the modified Aldrete≥9, and the time from the last administration to the discharge score ≥9.

Adverse eventstwo hours

abnormal clinical symptoms and vital signs, and abnormalities in laboratory tests

Incidence of postoperative amnesiatwo hours

incidence of anterograde and retrograde amnesia

Incidence of postoperative anxietytwo hours

incidence of patients with generalized Anxiety Disorder Scale (GAD-7) score ≥ 10

Incidence of postoperative vertigotwo hours

incidence of vertigo patients

Incidence of postoperative paintwo hours

incidence of patients with visual analogue scale (VAS) ≥ 4

Trial Locations

Locations (9)

Affiliated Tumor Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

Qinghai University Affiliated Hospital

🇨🇳

Xining, Qinghai, China

First Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine

🇨🇳

Xinjiang, Xinjiang, China

Shaanxi Provincial People's Hospital

🇨🇳

Xi'an, Shaanxi, China

The First Hospital of Lanzhou University

🇨🇳

Lanzhou, Gansu, China

Affiliated Hospital of Shaanxi University of traditional Chinese Medicine

🇨🇳

Xianyang, Shaanxi, China

Xian Yang Central Hospital

🇨🇳

Xi'an, Shaanxi, China

First Hospital of Shanxi Medical University

🇨🇳

Taiyuan, Shanxi, China

© Copyright 2025. All Rights Reserved by MedPath